Talimogene Laherparepvec

gene therapy

Identifier: CI-DRUG-00000797
Entity page: /drug/talimogene-laherparepvec ↗
Edges: 122

Neighbours: 22 cancers10 trials
Drawn: 32 of 32 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Talimogene Laherparepvec approved for …APPROVED_FOR1 of 1
→ approved for	Melanomacancer_family	supports	EMA indication text	Melanoma	1	Regulatory	ema	graph →
Talimogene Laherparepvec investigated for …INVESTIGATED_FOR8 of 8
→ investigated for

Talimogene Laherparepvec investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 70show all (up to 200)
→ investigated in trials for	Melanomacancer_family 14 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Soft Tissue Sarcoma 4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Soft Tissue Sarcoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cutaneous Melanoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cutaneous Melanoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Invasive Breast Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Invasive Breast Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Invasive Breast Carcinoma of No Special Type 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Invasive Breast Carcinoma of No Special Type	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Merkel Cell Carcinoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Merkel Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Skin Squamous Cell Carcinoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Skin Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Triple-Negative Breast Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Triple-Negative Breast Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Anaplastic Large Cell Lymphoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anaplastic Large Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Anaplastic Large Cell Lymphoma, ALK-Negative 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anaplastic Large Cell Lymphoma, ALK-Negative	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Anaplastic Large Cell Lymphoma, ALK-Positive 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anaplastic Large Cell Lymphoma, ALK-Positive	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Apocrine Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Apocrine Carcinoma	1	Observed	clinicaltrials	graph →

Talimogene Laherparepvec investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 70show all (up to 200)

→ investigated in trials for

Melanomacancer_family

14 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Melanoma

Observed

Talimogene Laherparepvec studied in …STUDIED_INderived10 of 43show all (up to 200)
→ studied in	NCT02923778Phase 2 · active not recruiting Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery · 43 trials list this drug (8 active)	—	—	Liposarcoma,Soft Tissue Sarcoma,Leiomyosarcoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · 43 trials list this drug (8 active)	—	—	Anaplastic Large Cell Lymphoma,Anaplastic Large Cell Lymphoma, ALK-Negative,Anaplastic Large Cell Lymphoma, ALK-Positive+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03069378Phase 2 · active not recruiting A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma · 43 trials list this drug (8 active)	—	—	Sarcoma,Epithelioid Sarcoma,Skin Angiosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06660810Phase 2 · active not recruiting Neoadjuvant Intralesional Injection of Talimogene Laherparepvec · 43 trials list this drug (8 active)	—	—	Soft Tissue Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02965716Phase 2 · active not recruiting Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma · 43 trials list this drug (8 active)	—	—	Melanoma,Cutaneous Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07102394Phase 1 · recruiting Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 · 43 trials list this drug (8 active)	—	—	Neurofibroma,Skin Neurofibroma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02779855Phase 1/Phase 2 · completed Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer · 43 trials list this drug (8 active)	—	—	Malignant Breast Neoplasm,Invasive Breast Carcinoma,Breast Ductal Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT04599062Phase 1/Phase 2 · active not recruiting TVEC and Preop Radiation for Sarcoma (8 ml Dose) · 43 trials list this drug (8 active)	—	—	Soft Tissue Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04163952Phase 1 · terminated Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin · 43 trials list this drug (8 active)	—	—	Skin Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03802604early Phase 1 · completed Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer · 43 trials list this drug (8 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths